Volume 124, Issue 5 , Pages 921-927, November 2009
Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma
Background
Children with severe/difficult-to-treat asthma experience high morbidity including frequent severe exacerbations. More knowledge is required to identify predictors of these exacerbations to reduce their occurrence.
Objective
To investigate the risk of future severe exacerbations (FSEs) in children with severe/difficult-to-treat asthma and recent severe exacerbations (RSEs).
Methods
We analyzed the occurrence and association of RSE (defined as 1 or more corticosteroid bursts during the 3 months before each of 3 annual visits) and FSE (defined as 1 or more corticosteroid bursts 6 or 12 months later) in children age 6 to 11 years in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens 3-year observational study. Repeated measures logistic regression analysis assessed the risk of FSE adjusted for demographics and clinical variables.
Results
In a multivariable model, FSE at 6 months was most strongly predicted by RSE (odds ratio [OR], 3.08; 95% CI, 2.21-4.28) and having 3 to 4 allergic triggers (OR, 2.05; 95% CI, 1.31-3.20). Race (OR, 1.77; 95% CI, 1.25-2.51) and being very poorly controlled according to the impairment component of the National Heart, Lung, and Blood Institute guidelines (OR, 1.59; 95% CI, 1.14-2.23) also significantly predicted FSE.
Conclusion
Recent severe asthma exacerbations are an important independent predictor of FSE in children with severe/difficult-to-treat asthma and should be considered when establishing asthma management plans.
Key words: Severe asthma, pediatric asthma, exacerbation, predictor of exacerbation, corticosteroid burst, long-term control
Abbreviations used: ATAQ, Asthma Therapy Assessment Questionnaire, FSE, Future severe exacerbation, HCU, Health care use, NHLBI, National Heart, Lung, and Blood Institute, OR, Odds ratio, PACT, Pediatric Asthma Controller Trial, PAQLQ(S), Pediatric Asthma Quality of Life Questionnaire With Standardized Activities, RSE, Recent severe exacerbation, TENOR, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
Support for third-party medical writing assistance was provided by Genentech USA, Inc, and Novartis Pharmaceuticals Corp.
Disclosure of potential conflict of interest: T. Haselkorn is a consultant for Genentech. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from AstraZeneca, Merck, GlaxoSmithKline, TEVA, Aerocrine, and the National Heart, Lung, and Blood Institute. B. E. Chipps is an advisor and/or speakers' bureau member for Alcon, Aventis, Genentech, AstraZeneca, Boehringer, GlaxoSmithKline, MedPoint, Novartis, Pfizer, Schering, Sepracor, and Merck and has received support for research and/or educational activities from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPoint, Novartis, Schering, Sepracor, and Merck. D. R. Mink is an employee of ICON Clinical Research, which receives research funding from Genentech. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, and Merck and has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, Ross Pharmaceuticals, and GlaxoSmithKline. F. E. R. Simons has received research support from the Canadian Institutes of Health Research and has consulted for Genentech. M. Massanari is an employee of Novartis. J. E. Fish is an employee of Genentech.
PII: S0091-6749(09)01335-9
doi:10.1016/j.jaci.2009.09.006
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 124, Issue 5 , Pages 921-927, November 2009
